Spyre Therapeutics, Inc.
Key Metrics
- Previous Close
- $93.81
- 52-Week Range
- $23.01 – $110.64
- Market Cap
- $9.64B
- P/E (TTM)
- —
- EPS (TTM)
- -2.49
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 10.08
- PEG Ratio
- —
- Return on Equity
- -35.03%
- Return on Assets
- -24.95%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 27.39
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-95.36M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $8.71B
Market Snapshot
About
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immunological and inflammatory diseases. The company is advancing a pipeline of product candidates targeting areas of significant unmet medical need. Spyre Therapeutics aims to bring novel treatment options to patients with serious immune-mediated conditions.